

# INVESTIGATING CARBOPLATIN CHEMOTHERAPY AS A POST-SURGICAL TREATMENT FOR SPLENIC HEMANGIOSARCOMA IN DOGS

*Complete Title: Investigating Carboplatin Chemotherapy as Adjuvant Treatment for Canine Splenic Hemangiosarcoma*

Dr Anthony Mutsaers

## Purpose of the Clinical Study

Hemangiosarcoma (HSA) is a type of blood vessel-based cancer that can affect the spleen in dogs. The disease is extremely aggressive and can spread quickly throughout the body. Even with standard of care treatments, Doxorubicin chemotherapy and tumour resection, HSA has a very guarded prognosis. Carboplatin is another common chemotherapy agent and has been shown to have a similar effect and an improved tolerability in dogs diagnosed with Osteosarcoma, when compared to Doxorubicin.

## Is Your Pet Eligible?

Dogs with a confirmed diagnosis of splenic HSA, that have already had a splenectomy, no prior chemotherapy treatment and no evidence of metastasis.

## Visits / Samples Required

Once every 3-4 weeks, your dog visit OVC for Carboplatin chemotherapy (4 treatments in total) and blood sample collection. Additional follow up and standard of care diagnostics including an x-ray and/or ultrasound may be recommended by the Oncology team for disease monitoring.

## Financial Incentives

Chemotherapy costs including the fee for administration and Carboplatin medication will be covered. Funding is generously provided by:

Ontario Veterinary College  
 **OVC PET TRUST**  
pettrust.ca



ONTARIO  
VETERINARY COLLEGE  
CLINICAL TRIALS



Questions about this study?

Please contact:

[ovc.clinicaltrials@uoguelph.ca](mailto:ovc.clinicaltrials@uoguelph.ca)